by Maria Zannes | Mar 6, 2023 | Articles, News
MARCH 6, 2023 The Empowered Patient podcast host Karen Jagoda recently interviewed bioAffinity Technologies President and CEO Maria Zannes about the development of the CyPath® Lung test for the detection of early-stage lung cancer. Hear the podcast at...
by Maria Zannes | Mar 6, 2023 | Events
MARCH 6, 2023 You’ve developed a great healthcare/life science idea, discovered a market for it and launched your business. Now what? The Health Cell’s monthly meeting Thursday, March 9, 2023, from 11:30 a.m. to 1 p.m. at the La Quinta Wyndham San Antonio Medical...
by Maria Zannes | Feb 22, 2023 | Articles, News
FEBRUARY 22, 2023 bioAffinity Technologies President and CEO Maria Zannes recently joined host Seth Farbman on his podcast From Start-Up to Stock Exchange. Listen here https://lnkd.in/g-vkTfKv to learn more about the need for early screening for lung cancer when it is...
by Maria Zannes | Sep 28, 2022 | Press Releases
SAN ANTONIO, TX – September 28, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the...
by Maria Zannes | Sep 6, 2022 | Press Releases
San Antonio, TX – September 6, 2022 – bioAffinity Technologies, Inc. (“bioAffinity” or the “Company”) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching...
